Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Rocklatan nouvelle génération

6 novembre 2026 mis à jour par: Alcon Research

Une étude de phase II, prospective, en deux étapes, à double insu, randomisée, multicentrique, contrôlée, dose-réponse, évaluant l'innocuité et l'efficacité hypotensive oculaire des solutions ophtalmiques AR-17043 et PG043 (AR-17043/Latanoprost) chez des sujets Avec une pression intraoculaire élevée

The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Aperçu de l'étude

Description détaillée

The study consists of two sequential stages under a single protocol. Stage 1 and Stage 2 will enroll independent participant cohorts. Subject enrolled in Stage 1 will not be eligible to participate in Stage 2.

During Stage 1, approximately 100 adult subjects with OAG or OHT will be randomized to 5 arms: 3 different concentrations of AR-17043, placebo comparator, or netarsudil 0.02% (Rhopressa®) for a treatment duration of 7 days.

During Stage 2, approximately 350 adult subjects with OAG or OHT will be randomized to 5 arms: low and high concentrations of PG043 (AR-17043/latanoprost 0.005%), AR-17043 high concentration, latanoprost, or netarsudil 0.02%/latanoprost 0.005% (Rocklatan®) for a treatment duration of 28 days.

Type d'étude

Interventionnel

Inscription (Réel)

646

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Alabama
      • Dothan, Alabama, États-Unis, 36301
        • Trinity Research Group
    • Arizona
      • Phoenix, Arizona, États-Unis, 85003
        • Eye Doctors of Arizona
    • California
      • Garden Grove, California, États-Unis, 92843
        • Orange County Ophthalmology Medical Group
      • Inglewood, California, États-Unis, 90301
        • United Medical Research Institute
      • Newport Beach, California, États-Unis, 92663
        • Eye Research Foundation
      • Petaluma, California, États-Unis, 94954
        • North Bay Eye Associates
    • Colorado
      • Fort Collins, Colorado, États-Unis, 80528
        • Eye Center of Northern Colorado, PC
    • Florida
      • Delray Beach, Florida, États-Unis, 33484
        • Glaucoma Specialists of South Florida
      • Delray Beach, Florida, États-Unis, 33484
        • Bruce A. Segal MD
      • Lakeland, Florida, États-Unis, 33805
        • Central Florida Eye Associates
      • Mt. Dora, Florida, États-Unis, 32757
        • Mid Florida Eye Center
      • Venice, Florida, États-Unis, 34285
        • Center For Sight
    • Georgia
      • Roswell, Georgia, États-Unis, 30076
        • Coastal Research Associates
    • Missouri
      • Kansas City, Missouri, États-Unis, 64154
        • Moyes Eye Center
    • New York
      • Rochester, New York, États-Unis, 14618
        • Rochester Ophthalmological Group
    • North Carolina
      • Winston-Salem, North Carolina, États-Unis, 27101
        • James D. Branch Ophthalmology
    • North Dakota
      • Fargo, North Dakota, États-Unis, 58103
        • Bergstrom Eye Research
    • Ohio
      • Cincinnati, Ohio, États-Unis, 45242
        • Cincinnati Eye Institute
      • Cincinnati, Ohio, États-Unis, 45236
        • Midwest Eye Center
    • Pennsylvania
      • Cranberry Township, Pennsylvania, États-Unis, 16066
        • Scott & Christie and Associates, PC
    • South Carolina
      • Mt. Pleasant, South Carolina, États-Unis, 29464
        • Carolina Eyecare Physicians LLC
    • Tennessee
      • Maryville, Tennessee, États-Unis, 37803
        • University Eye Specialists
      • Memphis, Tennessee, États-Unis, 38119
        • Total Eye Care PA
    • Texas
      • Dallas, Texas, États-Unis, 75243
        • Key-Whitman Eye Center
    • Virginia
      • Lynchburg, Virginia, États-Unis, 24502
        • Piedmont Eye Center

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Stage 1 Key Inclusion Criteria;

  • Diagnosis of OAG or OHT in both eyes.
  • High unmedicated IOP measurements in the study eye as specified in the protocol.
  • Corrected visual acuity equal to or better than +1.0 logMAR (Snellen equivalent equal to or better than 20/200) in the study eye.
  • Other protocol-specified inclusion criteria may apply.

Stage 2 Key Inclusion Criteria:

  • Diagnosis of OAG or OHT in both eyes.
  • High unmedicated IOP measurements in the study eye as specified in the protocol.
  • Corrected visual acuity equal to or better than +0.7 logMAR (Snellen equivalent equal to or better than 20/100) in the study eye.
  • Other protocol-specified inclusion criteria may apply.

Stage 1 and Stage 2 Key Exclusion Criteria:

  • Current use of more than 2 ocular hypotensive medications within 30 days (either eye).
  • Intraocular pressure greater than 36 millimeters mercury (mmHg) at Screening.
  • Glaucoma other than OAG.
  • Previous glaucoma surgery.
  • Any abnormality preventing reliable measurements.
  • Unable to demonstrate proper eyedrop instillation.
  • Other protocol-specified exclusion criteria may apply.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: AR-17043 low concentration (Stage 1)

AR-17043 Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7.

Investigational monotherapy

Expérimental: AR-17043 medium concentration (Stage 1)

AR-17043 Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7.

Investigational monotherapy

Expérimental: AR-17043 high concentration (Stage 1)

AR-17043 Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7.

Investigational monotherapy

Comparateur placebo: AR-17043 vehicle (Stage 1)

AR-17043 Vehicle, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7.

Placebo comparator

Comparateur actif: Rhopressa (Stage 1)

Netarsudil 0.02% Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7.

Marketed monotherapy

Autres noms:
  • Rhopressa®
Expérimental: PG043 low concentration (Stage 2)

PG043 Ophthalmic Solution, one drop in each eye in the evening on Days 1-28.

Investigational fixed dose combination

Expérimental: PG043 high concentration (Stage 2)

PG043 Ophthalmic Solution, one drop in each eye in the evening on Days 1-28.

Investigational fixed dose combination

Comparateur actif: AR-17043 high concentration (Stage 2)

AR-17043 Ophthalmic Solution, one drop in each eye in the evening on Days 1-28.

Investigational monotherapy

Comparateur actif: Latanoprost (Stage 2)

Latanoprost 0.005% Ophthalmic Solution, one drop in each eye in the evening on Days 1-28.

Marketed monotherapy

Autres noms:
  • Latanoprost
Comparateur actif: Rocklatan (Stage 2)

Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution, one drop in each eye in the evening on Days 1-28.

Marketed fixed dose combination

Autres noms:
  • Rocklatan®

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Mean diurnal IOP at Day 8 (Stage 1)
Délai: Day 8 (8:00, 10:00, 12:00, 16:00)

Intraocular pressure (IOP) will be measured with a Goldmann tonometer. Diurnal IOP will be calculated as the average of the four measurements.

Day 8 (8:00, 10:00, 12:00, 16:00)
Mean diurnal IOP at Day 29 (Stage 2)
Délai: Day 29 (8:00, 10:00, 16:00)

Intraocular pressure (IOP) will be measured with a Goldmann tonometer. Diurnal IOP will be calculated as the average of the three measurements.

Day 29 (8:00, 10:00, 16:00)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Mean IOP at each post-treatment timepoint (Stage 1)
Délai: Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)

Intraocular pressure (IOP) will be measured with a Goldmann tonometer at each post-treatment timepoint.

Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)
Mean change from the diurnally adjusted baseline IOP at each post-treatment timepoint (Stage 1)
Délai: Baseline (8:00, 10:00, 12:00, 16:00), Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)

Intraocular pressure (IOP) will be measured with a Goldmann tonometer at each post-treatment timepoint and compared to the time-relevant (corresponding) baseline measurement. Baseline is defined as the last visit prior to initiation of treatment.

Baseline (8:00, 10:00, 12:00, 16:00), Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)
Mean percent change from diurnally adjusted baseline IOP at each post-treatment timepoint (Stage 1)
Délai: Baseline (8:00, 10:00, 12:00, 16:00), Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)

Intraocular pressure (IOP) will be measured with a Goldmann tonometer at each post-treatment timepoint and compared to the time-relevant (corresponding) baseline measurement. Baseline is defined as the last visit prior to initiation of treatment.

Baseline (8:00, 10:00, 12:00, 16:00), Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)
Mean change from baseline mean diurnal IOP at each post-treatment timepoint (Stage 1)
Délai: Baseline (8:00, 10:00, 12:00, 16:00), Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)

Intraocular pressure (IOP) will be measured with a Goldmann tonometer. The baseline mean diurnal IOP will be calculated as the average of the four baseline measurements. Baseline is defined as the last visit prior to initiation of treatment.

Baseline (8:00, 10:00, 12:00, 16:00), Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)
Mean percent change from baseline mean diurnal IOP at each post-treatment timepoint (Stage 1)
Délai: Baseline (8:00, 10:00, 12:00, 16:00); Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)

Intraocular pressure (IOP) will be measured with a Goldmann tonometer. The baseline mean diurnal IOP will be calculated as the average of the four baseline measurements. Baseline is defined as the last visit prior to initiation of treatment.

Baseline (8:00, 10:00, 12:00, 16:00); Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)
Mean IOP at each post-treatment timepoint (Stage 2)
Délai: Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)

Intraocular pressure (IOP) will be measured with a Goldmann tonometer at each post-treatment timepoint.

Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)
Mean change from the diurnally adjusted baseline IOP at each post-treatment timepoint (Stage 2)
Délai: Baseline (8:00, 10:00, 16:00); Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)

Intraocular pressure (IOP) will be measured with a Goldmann tonometer at each post-treatment timepoint and compared to the time-relevant (corresponding) baseline measurement. Baseline is defined as the last visit prior to initiation of treatment.

Baseline (8:00, 10:00, 16:00); Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)
Mean percent change from diurnally adjusted baseline IOP at each post-treatment timepoint (Stage 2)
Délai: Baseline (8:00, 10:00, 16:00); Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)

Intraocular pressure (IOP) will be measured with a Goldmann tonometer at each post-treatment timepoint and compared to the time-relevant (corresponding) baseline measurement. Baseline is defined as the last visit prior to initiation of treatment.

Baseline (8:00, 10:00, 16:00); Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)
Mean change from baseline mean diurnal IOP at each post-treatment timepoint (Stage 2)
Délai: Baseline (8:00, 10:00, 16:00); Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)

Intraocular pressure (IOP) will be measured with a Goldmann tonometer. The baseline mean diurnal IOP will be calculated as the average of the three baseline measurements. Baseline is defined as the last visit prior to initiation of treatment.

Baseline (8:00, 10:00, 16:00); Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)
Mean percent change from baseline mean diurnal IOP at each post-treatment timepoint (Stage 2)
Délai: Baseline (8:00, 10:00, 16:00); Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)

Intraocular pressure (IOP) will be measured with a Goldmann tonometer. The baseline mean diurnal IOP will be calculated as the average of the three baseline measurements. Baseline is defined as the last visit prior to initiation of treatment.

Baseline (8:00, 10:00, 16:00); Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Directeur d'études: Clinical Trial Lead, Pharma, Alcon Research, LLC

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Liens utiles

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

4 septembre 2024

Achèvement primaire (Réel)

14 novembre 2025

Achèvement de l'étude (Réel)

14 novembre 2025

Dates d'inscription aux études

Première soumission

29 mai 2024

Première soumission répondant aux critères de contrôle qualité

29 mai 2024

Première publication (Réel)

4 juin 2024

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

9 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

6 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner